Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder

Journal of Clinical Psychopharmacology

Volumn 21, Issue 2, 2001, Pages 131-138

  Gladsjo, Julie Akiko ^a   Rapaport, Mark H ^a,b   McKinney, Rebecca ^a   Auerbach, Michelle ^c   Hahn, Tonya ^a,b   Rabin, Anthony ^d   Oliver, Tod ^a   Hazen, Andrea ^a   Judd, Lewis L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c MCLEAN HOSPITAL   (United States)

^d Napa State Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; PLACEBO;

ANXIETY NEUROSIS; ARTICLE; ATTENTION; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; LEARNING; LONG TERM CARE; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PANIC; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SEDATION; STATISTICAL ANALYSIS; VERBAL MEMORY; VISUAL MEMORY;

ADULT; ALPRAZOLAM; ANALYSIS OF VARIANCE; ANTI-ANXIETY AGENTS; ATTENTION; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PANIC DISORDER; PSYCHOMOTOR PERFORMANCE;

EID: 0035104492     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200104000-00003     Document Type: Article

References (40)

1. The amnesic action of benzodiazepines in man
2. Tranquillising memories: A review of the effects of benzodiazepines on human memory
3. Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests
4. Effects of chronic benzodiazepine administration on neuropsychological performance
5. Performance effects of di- azepam during and after prolonged administration
6. Adverse effects of benzodiazepines
7. A neuropsychological study of panic disorder: Negative findings
8. Cognitive impairment in longterm benzodiazepine users
9. Chronic use of benzodiazepines and psychomotor and cognitive test performance
10. Alpidem and lorazepam in the treatment of patients with anxiety disorders: Comparison of physiological and psychological effects
11. Neuropsychological changes during steady-state drug use, withdrawal and abstinence in primary benzodiazepine-dependent patients
12. Memory functions, alprazolam and exposure therapy: A controlled longitudinal study of agoraphobia with panic disorder
13. Lack of cognitive recovery following withdrawal from long-term benzodiazepine use
14. Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia
15. Memory for verbal and nonverbal stimuli in learning disability groups: Analysis by selective reminding
16. Validity of the trail making test as an indicator of organic brain disease
17. Componential analysis of problem solving ability: Performance of patients with frontal lobe damage and amnesic patients on a new sorting test
18. Group cognitive-behavioral treatment of panic disorder
19. Psychological treatment of panic: Work in progress on outcome, active ingredients, and follow-up
20. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation
21. Pharmacokinetics and psychomotor performance of alprazolam: Concentration-effect relationship
22. Clinical pharmacokinetics of alprazolam: Therapeutic implications
23. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
24. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects
25. Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine
26. Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation
27. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder
28. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder
29. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder